首页> 外文OA文献 >EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B‐Cell Lymphoma

【2h】

EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B‐Cell Lymphoma

机译：EMA审查Axicabtagene CileOleucel（Yescarta）用于治疗弥漫性大B细胞淋巴瘤

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Irene Papadouli; Jan Mueller‐Berghaus; Claire Beuneu; Sahra Ali; Benjamin Hofner; Frank Petavy; Kyriaki Tzogani; Anne Miermont; Koenraad Norga; Olga Kholmanskikh; Tim Leest; Martina Schuessler‐Lenz; Tomas Salmonson; Christian Gisselbrecht; Jordi Llinares Garcia; Francesco Pignatti;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma [J] . Irene Papadouli, Olga Kholmanskikh, Tim Leest, The oncologist . 2020,第10期

机译：EMA审查Axicabtagene CileOleucel（Yescarta）用于治疗弥漫性大B细胞淋巴瘤
2. axicabtagene ciloleucel (yescarta0) in certain types of lymphoma when other treatment options have been exhausted-A CAR T-cell therapy that increases the chances of survival but frequently provokes serious adverse effects [J] . Prescrire international . 2019,第208期

机译：在某些类型的淋巴瘤中，当其他治疗方案已经耗尽的汽车T细胞疗法时，轴颈特异菜（Yescarta0）在疲惫不堪的T细胞疗法增加，这增加了生存的机会，但经常引起严重的不良影响
3. Yescarta (R) (Axicabtagen Ciloleucel) receives EU Marketing Authorization for the Treatment of relapsed or refractory diffuse large B-Cell Lymphoma and primary mediastinal B-Cell Lymphoma after two or more previous systemic Therapies [J] . Oncology research and treatment. . 2018,第10期

机译：Yescarta（r）（Axicabtagen Ciloleucel）接受欧盟营销授权，用于治疗复发或难治性弥漫性大型B细胞淋巴瘤和原发性纵隔B细胞淋巴瘤后以前的两个或更多以前的全身治疗
4. Marker gene identification for gene expression analysis — Review and new findings for Diffused Large B Cell Lymphoma (DLBCL) [C] . Xi-Guang Wei, Ho-Chun Wu, Shing-Chow Chan International Conference on Digital Signal Processing . 2016

机译：用于基因表达分析的标记基因鉴定—扩散大B细胞淋巴瘤（DLBCL）的综述和新发现
5. Prognostic Biomarkers for Diffuse Large B Cell Lymphoma Patient Survival after Treatment with Chemotherapy: A Retrospective Analysis of 88 Cases [D] . Bushra, Hamama tul. 2019

机译：弥漫性大B细胞淋巴瘤化疗后患者生存的预后生物标志物：88例回顾性分析
6. EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B‐Cell Lymphoma [O] . Irene Papadouli, Jan Mueller‐Berghaus, Claire Beuneu, 2020

机译：EMA审查Axicabtagene CileOleucel（Yescarta）用于治疗弥漫性大B细胞淋巴瘤
7. Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy [O] . Victor A. Chow, Ajay K. Gopal, Jordan Gauthier, 2020

机译：在用不同的CD19导向汽车T细胞疗法之前治疗后复发或难治性淋巴瘤的AxicaBTAGENTAGENILOLEURETEL

EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B‐Cell Lymphoma

著录项

引文网络

相似文献

相关主题

期刊订阅